These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503 [TBL] [Abstract][Full Text] [Related]
3. B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. Hua D; Sun J; Mao Y; Chen LJ; Wu YY; Zhang XG World J Gastroenterol; 2012 Mar; 18(9):971-8. PubMed ID: 22408358 [TBL] [Abstract][Full Text] [Related]
4. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival. Sorrentino C; D'Antonio L; Fieni C; Ciummo SL; Di Carlo E Front Immunol; 2021; 12():778329. PubMed ID: 34975867 [TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4 Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E Front Immunol; 2019; 10():2936. PubMed ID: 31921188 [TBL] [Abstract][Full Text] [Related]
6. The Adaptive Immune Landscape of the Colorectal Adenoma-Carcinoma Sequence. Freitas JA; Gullo I; Garcia D; Miranda S; Spaans L; Pinho L; Reis J; Sousa F; Baptista M; Resende C; Leitão D; Durães C; Costa JL; Carneiro F; Machado JC Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575971 [TBL] [Abstract][Full Text] [Related]
7. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression. Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368 [TBL] [Abstract][Full Text] [Related]
8. Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging. Phillips D; Schürch CM; Khodadoust MS; Kim YH; Nolan GP; Jiang S Front Immunol; 2021; 12():687673. PubMed ID: 34093591 [TBL] [Abstract][Full Text] [Related]
9. PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors. Beyrend G; van der Gracht E; Yilmaz A; van Duikeren S; Camps M; Höllt T; Vilanova A; van Unen V; Koning F; de Miranda NFCC; Arens R; Ossendorp F J Immunother Cancer; 2019 Aug; 7(1):217. PubMed ID: 31412943 [TBL] [Abstract][Full Text] [Related]
10. Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model. Li J; Xu J; Yan X; Jin K; Li W; Zhang R Med Sci Monit; 2018 Aug; 24():5501-5508. PubMed ID: 30087314 [TBL] [Abstract][Full Text] [Related]
11. Low-dose total body irradiation facilitates antitumoral Th1 immune responses. Sonanini D; Griessinger CM; Schörg BF; Knopf P; Dittmann K; Röcken M; Pichler BJ; Kneilling M Theranostics; 2021; 11(16):7700-7714. PubMed ID: 34335959 [TBL] [Abstract][Full Text] [Related]
12. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826 [TBL] [Abstract][Full Text] [Related]
13. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737 [TBL] [Abstract][Full Text] [Related]
14. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565 [TBL] [Abstract][Full Text] [Related]
15. ASO Author Reflections: Analysis of PD-L1 Expression and Immunoscore in Colorectal Cancer. Yomoda T Ann Surg Oncol; 2019 Dec; 26(Suppl 3):658-659. PubMed ID: 31332636 [No Abstract] [Full Text] [Related]
16. PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells? Cantero-Cid R; Casas-Martin J; Hernández-Jiménez E; Cubillos-Zapata C; Varela-Serrano A; Avendaño-Ortiz J; Casarrubios M; Montalbán-Hernández K; Villacañas-Gil I; Guerra-Pastrián L; Peinado B; Marcano C; Aguirre LA; López-Collazo E BMC Cancer; 2018 Oct; 18(1):945. PubMed ID: 30285662 [TBL] [Abstract][Full Text] [Related]
17. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Yarchoan M; Huang CY; Zhu Q; Ferguson AK; Durham JN; Anders RA; Thompson ED; Rozich NS; Thomas DL; Nauroth JM; Rodriguez C; Osipov A; De Jesus-Acosta A; Le DT; Murphy AG; Laheru D; Donehower RC; Jaffee EM; Zheng L; Azad NS Cancer Med; 2020 Feb; 9(4):1485-1494. PubMed ID: 31876399 [TBL] [Abstract][Full Text] [Related]
18. Strategy to targeting the immune resistance and novel therapy in colorectal cancer. Gang W; Wang JJ; Guan R; Yan S; Shi F; Zhang JY; Li ZM; Gao J; Fu XL Cancer Med; 2018 May; 7(5):1578-1603. PubMed ID: 29658188 [TBL] [Abstract][Full Text] [Related]